Skip to main content

Table 2 Univariate and multivariate Cox proportional hazards regression analysis for risk of SDPTs by levels of serum biomarkers (Glucose, triglycerides, total cholesterol, GGT, and fructosamin)

From: Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort

 

Univariate

Multivariate**

p-value/trend

 

Variables

HR

95%CI

HR

95%CI

 

Clinical cut-offs

Glucose (6.11 mmol/L)

1.11

0.84–1.46

0.87

0.64–1.19

0.42

TG (1.71 mmol/L)

1.37

1.18–1.58

1.37

1.17–1.6

< 0.001

TC (6.5 mmol/L)

1.33

1.15–1.54

1.22

1.04–1.42

0.01

GGT (36 IU/L)

1.37

1.07–1.76

1.32

1.02–1.71

0.029

FAMN (2.5 mmol/L)

1.27

0.88–1.82

0.91

0.59–1.39

0.64

Quartiles

Gluc-q1 (< 4.6 mmol/L)

1

ref

1

ref

0.56

Gluc-q2 (4.6-5 mmol/L)

1.29

1.06–1.57

1.25

1.03–1.52

Gluc-q3 (5–5.4 mmol/L)

1.09

0.89–1.33

1.01

0.83–1.24

Gluc-q4 (> 5.4 mmol/L)

1.15

0.95–1.39

0.98

0.8–1.19

TC-q1 (< 5.2 mmol/L)

1

ref

1

ref

0.09

TC-q2 (5.2–5.8 mmol/L)

1.1

0.88–1.36

1.05

0.84–1.3

TC-q3 (5.8–6.6 mmol/L)

1.06

0.87–1.3

0.98

0.8–1.49

TC-q4 (> 6.6 mmol/L)

1.38

1.14–1.67

1.21

0.99–1.49

Tg-q1 (< 0.9 mmol/L)

1

ref

1

ref

0.004

Tg-q2 (0.9–1.3 mmol/L)

0.95

0.76–1.18

0.94

0.75–1.17

Tg-q3 (1.3–1.9 mmol/L)

1.11

0.91–1.34

1.08

0.88–1.31

Tg-q4 (> 1.9 mmol/L)

1.35

1.12–1.62

1.32

1.08–1.61

Ggt-q1 (< 16.79 IU/L)

1

ref

1

ref

0.27

Ggt-q2 (16.79–23.39 IU/L)

1.07

0.87–1.32

1.05

0.86–1.29

Ggt-q3 (23.39–35.99 IU/L)

1.05

0.86–1.29

0.99

0.8–1.22

Ggt-q4 (> 35.99)

1.24

1.01–1.52

1.15

0.93–1.42

Famn-q1 (< 2 mmol/L)

1

ref

1

ref

0.26

Famn-q2 (2–2.11 mmol/L)

0.88

0.69–1.11

0.84

0.66–1.07

Famn-q3 (2.11–2.25 mmol/L)

0.97

0.79–1.21

0.91

0.73–1.14

Famn-q4 (> 2.25 mmol/L)

0.99

0.8–1.24

0.85

0.67–1.07

  1. Abbreviations: Gluc glucose; TC total cholesterol; TG triglycerides; GGT gamma glutamyl transferase; FAMN fructosamine; PCa prostate cancer; SDPTs secondly diagnosed primary tumours; HR Hazard ratios; CI Confidence intervals
  2. **Adjusted for: Education, diabetes mellitus at PCa diagnosis, age, CCI, Fasting Status, time between date of blood test and PCa diagnosis date, PCa treatment: Hormonal, Radiotherapy, Radical prostatectomy